Credit Suisse Ag Aprea Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 14, 2021	SELL	$4.73 - $8.15 $160,706 - $276,904	-33,976 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$4.92 - $30.67 $111,684 - $696,209	22,700 Added 201.31%	33,976 $167,000
Q3 2020 Nov 13, 2020	BUY	$21.66 - $38.86 $244,238 - $438,185	11,276 New	11,276 $270,000
Q2 2020 Aug 12, 2020	SELL	$25.47 - $39.69 $715,401 - $1.11 Million	-28,088 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$31.65 - $45.3 $888,985 - $1.27 Million	28,088 New	28,088 $977,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,589
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.